Academics


Faculty Directory

Home > Academics > Faculty Directory

Eom, Hyeon Seok

Name
Eom, Hyeon Seok, M.D., Ph.D.(adjunct professor)
Faculty Appointment
(title, department)


Professor, Department of Cancer Biomedical Science, NCC-GCSP
Head, Center for Clinical Trials
Chief,Hematopoietic Stem Cell Transplantation Center
Head, Internal Medicine department, National Cancer Center, Korea
Area of Expertise
Hematologic malignancies/Transplantation immunobiology
Contact no
+82-31-920-2402
E-mail
hseom@ncc.re.kr
Highest Academic Qualification
Chief, Hematopoietic Stem Cell Transplantation Center, Hematology-Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center, Korea
Senior Scientist, Hematologic Malignancy Branch, Research Institute, Division of Translational & Clinical Research II, National Cancer Center, Korea
Head, Internal Medicine department, National Cancer Center, Korea
Previous Appointment(s) Held
Head, Internal Medicine department, National Cancer Center (2011-present)
Senior Scientist, Hematologic Malignancy Branch, Research Institute, Division of Translational & Clinical Research II, National Cancer Center, Korea (2007-2013)
Chief, Hematopoietic Stem Cell Transplantation Center, Hematology-Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center, Korea (2005-present)
Research Fellow, BMT section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA (2002-2004)
Assistant Professor, Department of Internal Medicine and Hemato-Oncology College of Medicine, The Catholic University of Korea (2001-2004)
Educational Background
Ph.D. The Catholic University Postgraduate School, Seoul, Korea (1997- 2001)
M.D. The Catholic University College of Medicine, Seoul, Korea (1983-1989)
M.M.S.The Catholic University Graduate School, Seoul, Korea (1991-1993)
Research Interests
Dr. Eom is a chief, Hematopoietic Stem Cell Transplantation Center, Hematology-Oncology Clinic. His research interests are focused on hematologic malignancies, especially lymphoma and multiple myeloma, and transplantation immunobiology. He was a senior scientist in Hematologic Malignancy Branch, Research Institute. He is interested in genetically modified donor lymphocyte infusion to the recipients who are in mixed chimera so that this DLI produce graft-vs.-lymphoma/myeloma effects without GVHD.
International Collaboration
Member, SWOG (2012–present)
2017 SCI-E Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma: Leukemia Lymphoma. Online:Published (2.755)

2017 SCI-E Clinical Implications of Quantitative JAK2V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms: Annals of Laboratory Medicine. 38:147~157 (2.174)

2017 SCI-E Prognostic role of the Neutrophil-to-lymphocyte ratio in patients with Primary Central Nervous System Lymphoma: oncotarget. Online:Published (5.168)

2017 SCI Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores: Annals of Hematology. Online:Published (3.083)

2017 SCI CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy: Experimental and Molecular Medicine. 49(7):e360~e360 (5.063)

2017 SCI-E Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection: Annals of Laboratory Medicine. 37(4):327~330 (2.174)

2017 SCI Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study: Leukemia. Online:Published (11.702)

2017 SCI-E Nationwide Statistical Analysis of Lymphoid Malignancies in Korea: Cancer Research and Treatment. Online:Published (3.772)

2017 SCI Nationwide Statistical Analysis of Lymphoid Malignancies in Korea.: Cancer Research and Treatment. Online:Published (3.772)

2017 SCI Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial: British Journal of Haematology. 176(5):743~749 (5.67)

2016 SCI-E Prognostic Implications of Monosomies in Patients With Multiple Myeloma: Clinical lymphoma, myeloma & leukemia. 17(3):159~164 (2.316)

2016 SCI-E Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.: Cancer Medicine. 6(1):100~108 (2.915)

2016 SCI-E Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008): Oncotarget. 7(51):85584~85591 (5.008)

2016 SCI-E Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.: Oncotarget. 7(44):72033~72043 (5.008)

2016 SCI The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B-cell lymphoma patients with elevated serum lactate dehydrogenase: Annals of hematology. 95(9):1491~1501 (3.022)

2016 SCI-E Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.: Clinical Lymphoma Myeloma and Leukemia. 16(9):527535~527535 (2.316)

2016 SCI Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosomepositive acute lymphoblastic leukemia: Annals of Oncology. 27(6):1081~1088 (9.269)

2016 SCI The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea: Annals of hematology. 95(6):911~919 (3.022)

2016 SCI Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors: Journal of Immunotherapy. 39(3):140~148 (3.712)

2016 SCI A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas: Annals of Oncology. 27(4):712~718 (9.269)

2016 SCI Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study: Annals of hematology. 95(4):603~611 (3.022)

2015 SCI-E Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone or high-dose cyclophophamide plus G-CSF: Leukemia & Lymphoma. 57(6):1389~1397 (2.891)

2015 SCI Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma: Haematologica. 101(3):363~370 (5.814)

2015 기타 A Case of Washed Platelet Transfusion in a Patient with History of Recurrent Transfusion Reaction: The Korean Journal of Blood Transfusion (대한수혈학회지). 26:316~322 (0)

2015 기타 Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012: BLOOD RESEARCH. 50(4):204~217 (0)

2015 SCI-E A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial: Leukemia & Lymphoma. Online:Published (2.891)

2015 SCI-E Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma: Annals of Laboratory Medicine. 35:563~569 (1.417)

2015 SCI Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL: Blood. 126:1893~1901 (10.452)

2015 기타 Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation.: Blood Research. 50:160~166 (0)

2015 SCI-E The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea: The Korean Journal of Internal Medicine. 30:675~683 (1.426)

2015 SCI Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia: Blood. 126:746~756 (10.452)

2015 기타 A Patient with Philadelphia-Negative Acute Lymphoblastic Leukemia with a FISH-Negative Cryptic BCR-ABL1 Rearrangement Detected by PCR and Sequencing Analysis: Hematology & Transfusion International Journal. 1:00014~00014 (0)

2015 SCI Teaching NeuroImages: Periventricular restricted diffusion MRI in CMV ventriculitis: Neurology. 84(16):e121~e121 (8.286)

2015 SCI Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.: Annals of hematology. 94(4):617~625 (2.634)

2015 SCI Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma: Cancer letters. 356(2PtB):743~750 (5.621)

2014 기타 Network Computer Management System Development for Blood Transfusion in ABO-Incompatible Stem Cell Transplantation: The Korean Journal of Blood Transfusion. 25(3):283~290 (0)

2014 SCI Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.: Annals of Hematology. 93(11):1895~1901 (2.396)

2014 SCI-E Rapid Sequential Gain of ABL1 Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia: Annals of laboratory medicine. 34:399~401 (1.481)

2014 기타 Clinical Effects and Safety of Therapeutic Leukapheresis in Hyperleukocytosis: The Korean Journal of Blood Transfusion. 25(2):132~140 (0)

2014 SCI Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robustic prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.: Annals of hematology. 93(8):1353~1361 (2.396)

2014 기타 R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma: Blood research. 49(2):107~114 (0)

2014 SCI-E Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma: BioMed Research International. 2014:1~8 (2.706)

2014 SCI-E Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenstrom Macroglobulinemia in Korea: Biomed Research International. 2014:1~7 (2.706)

2014 SCI-E Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma: Biomed Research International. 2014:145619~145619 (0)

2014 SCI Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma: Journal of Nuclear Medicine. 55(2):216~222 (5.563)

2014 SCI Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients: Annals of hematology. 93(1):113~121 (2.396)

2013 기타 Assessment of effects of phlebotomy in patients with polycythemia vera and secondary polycythemia: 대한수혈학회지. 24(3):265~274 (0)

2013 SCI A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas: Investigational new drugs. 31(6):1514~1521 (3.498)

2013 SCI Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.: European Journal of Cancer. 49(16):3486~3496 (5.061)

2013 SCI-E Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement: Journal of hematology and oncology. 6(1):76~76 (4.458)

2013 SCI The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network: Leukemia Research. 37(9):1070~1076 (2.764)

2013 SCI Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia: Annals of hematology. 92(8):1101~1110 (2.866)

2013 SCI Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B cell lymphoma: Journal of Clinical Oncology. 31(17):2103~2109 (18.083)

2013 SCI Repeated radioimmunotherapy with 131 I-rituximab for patients with low grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma: Cancer Chemotherapy and Pharmacology. 71:945~953 (2.795)

2013 SCI Adenovirus expressing both thymidine kinase and soluble PD1 enhances anti-tumor immunity by strengthening CD8 T cell response: Molecular Therapy. 21(3):688~695 (7.041)

2013 SCI Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.: Bone marrow transplantation. 48(3):425~432 (3.541)

2013 SCI-E Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation: Ann Transplant. 18:36~42 (0.815)

2012 SCI-E Prognostic factors in primary diffuse large B cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphomas (CISL): Journal of Hematology & Oncology. 5(1):49~49 (3.99)

2012 SCI Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models: Blood. 119(24):5678~5687 (9.898)

2012 기타 Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008.: Korean Journal of Hematology. 47:28~38 (0)

2012 SCI VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma: Cancer Science. 103(3):497~503 (3.325)

2012 SCI Clinical features and outcomes of Hodgkin's lymphoma in Korea : Consortium for Improving Survival of Lymphoma(CISL): Annals of Hematology. 91(2):223~233 (2.615)

2012 SCI Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplantation and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial: Annals of Hematology. 91(2):249~256 (2.615)

2011 SCI Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse B-cell lymphoma in patients treated with rituximab plus chemotherapy: International Journal of Cancer. 131(1):235~243 (5.444)

2011 SCI Phase II trial of rituximab plus CVP combination chemotherpy for advanced stage marginal zone B cell lymphoma as a first line therapy: Consortium for Improving Survial of Lymphoma (CISL) study.: Annals of Hematology. 91(4):543~551 (2.615)

2011 SCI Comparative analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia: Acta Haematologica. 127(2):81~89 (1.354)

2011 SCI-E Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy: Journal of Hematology & Oncology. 4:34~34 (3.99)

2011 SCI-E Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a radomized phase 3 trial.: Lancet Oncology. 12:773~784 (22.589)

2011 SCI Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients: Annals of Oncology. 22(2):411~416 (6.452)

2011 SCI Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial: Investigational New Drugs. 29(1):154~160 (3.007)

2011 SCI Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias: Leukemia Research. 35(1):e6~e7 (2.555)

2010 SCI Stage IV marginal zone B-cell lymphoma-prognostic factors and the role of rituximab: consortium for improving survival of lymphoma (CISL): Cancer Science. 101:2443~2447 (3.771)

2010 SCI-E Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study: International Journal of Hematology. 92:510~517 (1.168)

2010 SCI Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report: Leukemia Research. ;34(9):1175~1179 (2.358)

2010 SCI Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood: Leukemia research. 34(9):1127~1231 (2.358)

2010 SCI Comparative analysis of outcomes of allogeneic perpheral blood stem cell transplantation from related and unrelated donors: Annals of Hematology. 89(8):813~820 (2.919)

2010 SCI-E Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party: International Journal of Hematology. 92(1):52~57 (1.168)

2010 SCI-E Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for improving survival of lymphoma (CISL) study: BMC cancer. 10:321~321 (2.736)

2010 SCI Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP): Annals of Hematology. 89(5):489~497 (2.919)

2010 SCI-E Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: A report of 2 cases with a review of the literature: The Korean Journal of Laboratory Medicine. 30:117~121 (0.626)

2010 SCI Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B cell lymphoma: Cancer Genetics and Cytogenetics. 198:40~46 (1.537)

2010 SCI Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin: Journal of pathology. 220(4):446~451 (6.466)

2010 SCI Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling: BMC Cancer. 10:55~55 (2.736)

2010 SCI Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide: Annals of Hematology. 89:201~206 (2.919)

2010 SCI DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population: Cancer genetics and cytogenetics. 196(1):31~37 (1.537)

2010 SCI Mutational analysis of UBR5 gene encoding an E3 ubiquitin ligase in common human cancers: Pathology. 42:93~94 (2.673)

2010 SCI Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers: APMIS. 118:83~84 (1.745)

2010 SCI Somatic mutation of PIK3R1 gene is rare in common human cancers: Acta Oncologica. 49:125~127 (2.265)

2009 SCI Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study: Journal of Clinical Oncology. Online:Published (17.157)

2009 SCI Absence of IDH2 codon 172 mutation in common human cancers: International Journal of Cancer. 125:2485~2486 (4.734)

2009 SCI Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry: Acta Haematologica. 122:200~210 (1.191)

2009 SCI-E Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma: Japanese Journal of Clinical Oncology. 39:449~455 (1.405)

2009 SCI A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma: Cancer Chemotherapy and Pharmacology. 64:27~33 (2.74)

2009 SCI Somatic mutation of GNAQ gene is rare in common solid cancers and leukemias: Acta Oncologica. 23:1~2 (2.739)

2009 SCI Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas: Acta Oncologica. 7:1~2 (2.739)

2009 SCI Analysis of NOTCH1 extracellular juxtamembrane expansion mutations in acute leukemias and multiple myelomas: APMIS. 117:147~148 (1.316)

2008 SCI ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/ vincristine/prednisone chemotherapy: Cancer science. 99:2496~2501 (3.165)

2008 SCI Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma: Annals of Oncology. Online:Published (4.875)

2008 SCI The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells: Journal of Immunology. 181:6820~6828 (6.068)

2008 기타 Do PML/RAR-α isoforms have clinical significance in patients with acute promyeloctyic leukemia?: 대한내과학회지. 75:409~411 ()

2008 SCI Description of a novel HLA-Cw*03 allele, HLA-Cw*0349, identified in a Korean individual: Tissue Antigens. ONLINE:PUBLISHED~ (2.245)

2008 SCI Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma: Cytokine. 43:71~75 (2.169)

2008 SCI Reference intervals for circulating angiogenic cytokines.: Clinical Chemistry and Laboratory Medicine. 46:545~550 (1.741)

2007 SCI Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: Bone Marrow Transplantation. 40:919~924 (2.621)

2007 SCI Consideration of aggressive therapeutic strategies for primary testicular lymphoma: American Journal of Hematology. 82:840~845 (1.882)

2006 SCI Neural Stem Cell Transplant Survival in Brains of Mice: Assessing the Effect of Immunity and Ischemia by using Real-time Bioluminescent Imaging: Radiolgy. 241:822~830 (5.251)

2006 SCI Host MHC Class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions: Blood. 108:2106~2113 (10.37)

2005 SCI T Cell P/E-selectin Ligand (1,3)fucosylation Is Not Required For GVHD Induction: Experimental Hematology. 33:1564~1573 (3.408)

2003 기타 Effects of cyclosporin A, FK506, and 3-deazaadenosine on acute graft-versus-host disease and survival in allogeneic murine hematopoietic stem cell transplantation: Immune network. 3(2):130~155 ()

2003 기타 A case of hyperammonemic encephalopathy with serum amino acid alteration in multiple myeloma: The Korean Journal of Hematology. 38(1):64~67 ()

2003 SCI Cyclosporin A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome: Acta Haematologica. 110:36~40 (1.564)

2002 기타 A case of Waldenstrom’s macroglobulinemia treated with 2-Chlorodeoxyadenosine (Cladribine): The Korean Journal of Hematology. 37(3):227~230 ()

2001 기타 The effects of activated NK cells supplement on graft-versus-leukemia and graft-versus-disease in allogeneic BMT within the leukemic mouse model: Korean J Hematopoietic Stem Cell Transplantation. 6(1):51~64 ()

2001 기타 A case of high risk primary systemic amyloidosis and literature review on the trials hematopoietic stem cell transplantation in primary systemic amyloidosis: Korean J Hematopoietic Stem Cell Transplantation. 6(2):202~210 ()

2001 기타 Rotor off fraction might contribute early platelet recovery after syngeneic transplantation in mouse: The Korean Journal of Hematology. 36(3):232~240 ()

2001 기타 Busulfan, thiotepa, and melphalan as a conditioning regimen for allogeneic bone marrow transplantation in patients with acute myelogenous leukemia. The Korean Journal of Internal Medicine: The Korean Journal of Internal Medicine. 60(2):156~166 ()

2001 기타 Expression patterns of green fluorescence protein (GFP) after the intravenous injection with adenovirus injection with adenovirus vector in mouse organs: The Korean Journal of Internal Medicine. 61(5):537~545 ()

2001 SCI Conditioning with high-dose cyclophosphamide may not be sufficient to provide a long-term remission of paroxysmal nocturnal hemoglobinuria following syngeneic peripheral blood stem cell transplantation: Bone Marrow Transplantation. 28:987~988 (2.621)

2000 기타 Depression and pain in patients with cancer – a preliminary study: J Korean Neuropsychiatr Assoc. 39(6):1122~1131 ()

2000 기타 A case of primary bone marrow lymphoma secondary to aplastic anemia: The Korean Journal of Hematology. 35(2):171~173 ()

2000 기타 In vivo expression of murine thrombopoietin (TPO) cDNA transduced into marrow cells by adenovectors in murine allogeneic bone marrow transplantation model: Korean J BRM. 10(2):193~206 ()

2000 기타 Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome: The Korean Journal of Internal Medicine. 15(2):122~126 ()

2000 기타 Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.: The Korean Journal of Internal Medicine. 15(3):224~231 ()

1999 기타 A preliminary report of allogeneic stem cell transplantation for patients with acute leukemia conditioned by triple-alkylating regimen: The Korean Journal of Hematology. 34(2):288~296 ()

1999 기타 Autologous or allogeneic bone marrow transplantation compared with consolidation chemotherapy in acute promyelocytic leukemia: Journal of Korean Cancer Association. 31(1):153~164 ()

1999 기타 Expression of multidrug resistant genes in bone marrow mononuclear cells of patients with myeloid leukemia: Journal of Korean Cancer Association. 31(2):331~338 ()

1999 기타 Allogeneic Bone Marrow Transplantaion from A Partially Mismatched Related Donor: Korean J Hematopoietic Stem Cell Transplantation. 4(1):73~82 ()

1999 기타 Effects of induction chemotherapy with BHAC plus idarubicin on long-term survival for patients with acute myelogenous leukemia according to different postremission strategies.: The Korean Journal of Hematology. 34(2):317~325 ()

1998 기타 Comparison of 4 different methods for flow cytometric quantitation of CD34+ cell.: Korean J Hematopoietic Stem Cell Transplantation. 3(2):241~251 ()

1998 기타 Allogeneic bone marrow transplantation for patients in accelerated phase of chronic myelogenous leukemia.: Korean J Hematopoietic Stem Cell Transplantation. 3(2):153~161 ()

1998 기타 Autologous peripheral blood stem cell and bone marrow transplantations for acute leukemia in first remission: Korean J Hematopoietic Stem Cell Transplantation. 3(1):63~74 ()

1998 기타 Impact of induction chemotherapy regimen on the outcome after allogeneic stem cell transplantation for patients with AML in first remission: Korean J Hematopoietic Stem Cell Transplantation. 3(2):173~183 ()

1998 기타 Allogeneic hematopoietic stem cell transplantation using in vivo expanded bone marrow by G-CSF: Korean J Hematopoietic Stem Cell Transplantation. 3(2):193~201 ()

1998 기타 Comparison of CFU-Mk colony forming potential between normal bone marrow and G-CSF-mobilized peripheral blood mononuclear cells: Korean J BRM. 8(2):207~213 ()

1997 기타 Secondary malignancies after bone marrow transplantation: Korean J Hematopoietic Stem Cell Transplantation. 2(1):133~138 ()

1997 기타 Treatment of multiple myeloma with autologous peripheral blood stem cell transplantation: Korean J Hematopoietic Stem Cell Transplantation. 2(1):17~24 ()

1997 기타 Unrelated bone marrow transplantation in patients with hematological malignancies.: Korean J Hematopoietic Stem Cell Transplantation. 2(1):25~35 ()

1997 기타 High Dose Therapy and autologous stem cell transplantation as compared with salvage chemotherapy in relapsed or refractory patients with non-Hodgkin's lymphoma: Korean J Hematopoietic Stem Cell Transplantation. 2(1):63~71 ()

1997 기타 Comparison of effects of low molecular weight starch (pentastarch) and high molecular weight starch (hetastarch) on RBC sedimentation and hematopoietic stem cell colony formation.: Korean J Hematopoietic Stem Cell Transplantation. 1(2):25~32 ()

1997 기타 COP-BLAM (Cyclophosphamide/Vincristine/Prednisone/Bleomycin/Adriamycin /Procarbazine) combination chemotherapy for the treatment of patient's with intermediate-or high-grade non-Hodgkin's lymphoma.: Korean J Hematopoietic Stem Cell Transplantation. 2(1):73~80 ()

list

top